Welcome
Support Centre
23 April 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
A double blind placebo controlled trial of the effect of perindopril on muscle strength and functional capacity in older people
ISRCTN ISRCTN67679521
DOI 10.1186/ISRCTN67679521
ClinicalTrials.gov identifier
EudraCT number
Public title A double blind placebo controlled trial of the effect of perindopril on muscle strength and functional capacity in older people
Scientific title
Acronym N/A
Serial number at source CZB/4/88
Study hypothesis Physical function and exercise capacity decline with age and are a major source of disability in older people. Recent evidence suggests a potential role for the renin-angiotensin system in modulating muscle function. We sought to examine the effect of the angiotensin converting enzyme (ACE) inhibitor perindopril on physical function in elderly people with functional impairment who had no heart failure or left ventricular systolic dysfunction.
Lay summary
Ethics approval The study was approved by the Tayside Committee on Medical Research Ethics.
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Sarcopenia
Participants - inclusion criteria Older people over the age of 65 years with some dependence in activities of daily living.
Participants - exclusion criteria Excluded are those without left ventricular systolic dysfunction, those already receiving an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II inhibitor, those with a contraindication to ACE inhibitors and those unable to give informed consent.
Anticipated start date 06/08/2003
Anticipated end date 06/02/2006
Status of trial Completed
Patient information material
Target number of participants 148
Interventions Perindopril or placebo given for a period of 20 weeks.
Primary outcome measure(s) Change in the 6-minute walking distance over the 20 weeks.
Secondary outcome measure(s) 1. Changes in muscle function
2. Daily activity levels
3. Self-reported function
4. Health-related quality of life
Sources of funding Chief Scientist Office of the Scottish Executive Health Department (UK) (ref: CZB/4/88)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17923654
Contact name Prof  Marion  McMurdo
  Address Head of Section of Ageing & Health
Ninewells Hospital and Medical School
  City/town Dundee
  Zip/Postcode DD1 9SY
  Country United Kingdom
Sponsor Chief Scientist Office of the Scottish Executive Health Department (UK)
  Address St Andrew's House
  City/town Edinburgh
  Zip/Postcode EH1 3DG
  Country United Kingdom
  Sponsor website: http://www.sehd.scot.nhs.uk/cso/
Date applied 25/01/2005
Last edited 18/10/2007
Date ISRCTN assigned 31/03/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.